Skip to main content Skip to search Skip to main navigation

EMA: Update of the GACP Guideline Published

The guideline on Good Agricultural and Collection Practice (GACP) for herbal starting materials has been in place since 2006 to ensure consistent quality of herbal substances. The newly released Revision 1 updates the document to current standards, reflecting developments over the past decade such as the growing use of indoor cultivation technologies and published legal interpretations. In addition, Annex 1 introduces specific requirements for indoor cultivation practices.

Indoor cultivation facilities should contain adequate systems for air, climate and humidity control, light, water treatment, ventilation and air filtration systems. They are designed to:

  • Control access to personnel;
  • Minimise potential contamination;
  • Facilitate cleaning, maintenance and other operations;
  • Be impermeable to cleaning and disinfecting agents.

For documentation, the new Annex 1 stipulates:

  • Documentation of all relevant conditions, materials, and processes
  • Batch-specific acceptance criteria for cultivation & production
  • SOP-based document management including retention rules
  • Product specifications per batch defined and recorded
  • Cleaning activities documented in batch records/logbooks
  • Daily digital records of critical process parameters for indoor cultivation

Regarding crop maintenance and plant protection, Annex 1 stipulates:

  • Written procedures for material receipt, storage, handling, sampling, approval/rejection
  • Validation of processes, cleaning, and responsibilities documented
  • Calibration of all cultivation equipment per schedule
  • Material approval before each new cultivation cycle by QA
  • Indoor cultivation: Identify critical quality attributes (CQA) & process parameters (CPP)
  • Define in-process criteria and controls
  • Standardize cultivation process
  • Complete qualification of critical equipment and supporting systems

Source:

EMA: Good agricultural and collection practice for starting materials of herbal origin - Scientific guideline


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next